ストックスクリーナーアプリを入手
2.92
4.66%
0.13
アフターアワーズ：
2.90
-0.02
-0.68%
前日終値:
$2.79
開ける：
$2.77
24時間の取引高:
446.76K
Relative Volume:
0.69
時価総額：
$209.14M
収益：
-
当期純損益:
$-104.08M
株価収益率:
-2.0755
EPS:
-1.4069
ネットキャッシュフロー:
$-89.91M
1週間 パフォーマンス:
+5.80%
1か月 パフォーマンス:
+29.20%
6か月 パフォーマンス:
+6.96%
1年 パフォーマンス:
+37.09%
1日の値動き範囲:
$2.75
$2.93
1週間の範囲:
$2.62
$2.93
52週間の値動き範囲:
$1.70
$3.72
Nkarta Inc Stock (NKTX) Company Profile
名前
Nkarta Inc
セクター
電話
(925) 407-1049
住所
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
2.92 | 176.91M | 0 | -104.08M | -89.91M | -1.4069 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-15 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-10-09 | 開始されました | Rodman & Renshaw | Buy |
| 2024-08-14 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-03-22 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-10-10 | 開始されました | Canaccord Genuity | Buy |
| 2022-07-28 | 開始されました | Needham | Buy |
| 2022-07-18 | 開始されました | SVB Leerink | Outperform |
| 2022-03-11 | 開始されました | Raymond James | Outperform |
| 2022-03-08 | 開始されました | H.C. Wainwright | Buy |
| 2022-01-06 | 開始されました | William Blair | Outperform |
| 2021-11-18 | 開始されました | SMBC Nikko | Outperform |
| 2021-07-16 | 開始されました | Oppenheimer | Outperform |
| 2020-08-04 | 開始されました | Cowen | Outperform |
| 2020-08-04 | 開始されました | Evercore ISI | Outperform |
| 2020-08-04 | 開始されました | Mizuho | Buy |
| 2020-08-04 | 開始されました | Stifel | Buy |
すべてを表示
Nkarta Inc (NKTX) 最新ニュース
NKARTA STOCK : BIG PRICE RECOVERY | NKTX STOCK Rinku Singh (yKkQAHM32g) - Mshale
Nkarta Inc (NASDAQ: NKTX) Stock Price, News & Analysis - Kalkine
Monaco Asset Management SAM Makes New Investment in Nkarta, Inc. $NKTX - MarketBeat
Nkarta (NASDAQ:NKTX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Stifel cuts Nkarta stock price target on updated model By Investing.com - Investing.com Australia
Stifel cuts Nkarta stock price target on updated model - Investing.com
Stifel Nicolaus Has Lowered Expectations for Nkarta (NASDAQ:NKTX) Stock Price - MarketBeat
Nkarta Inc. (NKTX) Edges Higher as Biotech Stock Holds Key Support ZoneEase of Movement - Vinanet
Equities Analysts Set Expectations for Nkarta Q3 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Rocket Pharmaceuticals (RCKT) - The Globe and Mail
Nkarta, Inc. Stock 12‑Month Price Target Cut to $11, Implies 347% Upside - TradingView
H.C. Wainwright cuts Nkarta stock price target on trial progress - Investing.com
H.C. Wainwright cuts Nkarta stock price target on trial progress By Investing.com - Investing.com Australia
NKARTA, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $14 FROM $16 - Bitget
NKTX Q2 2026 Earnings: Wider Loss of $0.54 Per Share Misses Estimates as Clinical-Stage Costs EscalateFinancial Data - vinanet.vn
Nkarta, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Nkarta (NASDAQ:NKTX) Posts Quarterly Earnings Results, Misses Estimates By $0.18 EPS - MarketBeat
Nkarta Q2 EPS of $(0.54) misses $(0.38) analyst estimate - scanx.trade
Nkarta Reports Continued Enrollment in Ntrust Autoimmune Trials and $243.2 Million Cash Position, Reaffirms Runway Into 2029 - Quiver Quantitative
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights - GlobeNewswire
Nkarta, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
NKTX Q1 2026 Earnings: Narrower-Than-Expected Loss Supports 5.24% Share GainROIC Trend Report - vinanet.vn
Nkarta, Inc. expected to post a loss of 38 cents a shareEarnings Preview - TradingView
NKTX Q1 2026 Earnings: Narrower-than-Expected Loss Drives 4.09% RallyEPS Miss Report - vinanet.vn
Nkarta Inc (NKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nkarta (NKTX) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Nkarta Inc. (NKTX) Drops 2.79% to $2.09 as Key Support Level Comes into FocusLate Stage Breakouts - dars.gov.et
Nkarta (NASDAQ:NKTX) Upgraded at Wall Street Zen - MarketBeat
Nkarta Stock Price Forecast. Should You Buy NKTX? - StockInvest.us
Nkarta Inc. (NKTX) Slides 3.26% as Clinical-Stage Biotech Faces Resistance TestAI Trade Signals - dars.gov.et
Nkarta, Inc. Revenue Breakdown – NASDAQ:NKTX - TradingView
NKTX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Nkarta Inc (NKTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NKTX|Nkarta Inc|Price:2.245|Chg%:-0.025 - TradingKey
Nkarta Inc (NKTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nkarta Inc. (NKTX) Edges Higher: Biotech Stock Tests Key Levels After 3.5% GainAnchored VWAP - dars.gov.et
Nkarta Market Sentiment - Benzinga España
Nkarta Inc (NKTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nkarta Inc (NKTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nkarta Inc (NKTX) Balance Sheet - TradingKey
NKTX|Nkarta Inc|Price:2.430|Chg%:-0.110 - TradingKey
Nkarta Inc (NKTX) Cash Flow - TradingKey
Nkarta Inc (NKTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NKTX Q1 2026 Earnings: EPS Beat as Developmental-Stage Biotech Focuses on Pipeline ExecutionSubscription Growth Report - vinanet.vn
Nkarta Inc. (NKTX) Holds Steady at $2.6 as Consolidation ContinuesPassive Flow - dars.gov.et
Nkarta Inc. (NKTX) Holds Steady at $2.60 Amid Consolidation PhaseScalping Stock Signals - dars.gov.et
Nkarta Inc. (NKTX) Declines 4.9% as Biotech Headwinds Persist — Key Support in FocusTICK Divergence - dars.gov.et
Nkarta Inc. (NKTX) Slides 5% as Biotech Momentum Fades, Tests Near-Term SupportAccumulation Line - dars.gov.et
Nkarta Inc. (NKTX) Surges 8.6% as Biotech Sentiment ImprovesAlgorithmic Stock Picks - dars.gov.et
NKTX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Double-Digit Stock GainProfit Growth Outlook - dars.gov.et
Nkarta Inc (NKTX) 財務データ
収益
当期純利益
現金流量
EPS
Nkarta Inc (NKTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| HASTINGS PAUL J | Chief Executive Officer |
Jan 15 '26 |
Sale |
2.07 |
26,046 |
53,915 |
390,023 |
| Mahmood Nadir | President |
Jan 15 '26 |
Sale |
2.07 |
5,649 |
11,693 |
167,727 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):